BRCA1 and pancreatic neoplasm: Golan et al. [40] analyzed 71 patients with BRCA1/2-asssociated pancreatic cancer and observed an improvement in survival in patients with advanced disease (stage 3 and 4) who had received platinum-based therapy in comparison to those patients who were not treated with these agents.